Home » Stocks » Stemline Therapeutics

Stemline Therapeutics, Inc. (STML)

Jun 10, 2020 - STML was delisted (reason: company went private)
Stock Price: $11.83 USD 0.00 (0.00%)
Updated Jun 10, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 621.13M
Revenue (ttm) 47.04M
Net Income (ttm) -70.70M
Shares Out 52.51M
EPS (ttm) -1.58
PE Ratio n/a
Forward PE 17.92
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jun 10, 2020
Last Price $11.83
Previous Close $11.83
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 11.82 - 12.10
Day's Volume 0
52-Week Range 3.21 - 18.22

More Stats

Market Cap 621.13M
Enterprise Value 470.72M
Earnings Date (est) Jul 31, 2020
Ex-Dividend Date n/a
Shares Outstanding 52.51M
Float 37.29M
EPS (basic) -1.58
EPS (diluted) -1.58
FCF / Share -1.24
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.28M
Short Ratio 1.13
Short % of Float 6.83%
Beta 1.74
PE Ratio n/a
Forward PE 17.92
P/FCF Ratio n/a
PS Ratio 13.20
PB Ratio 4.21
Revenue 47.04M
Operating Income -73.16M
Net Income -70.70M
Free Cash Flow -59.33M
Net Cash 150.41M
Net Cash / Share 2.86
Gross Margin -26.36%
Operating Margin -155.52%
Profit Margin -150.30%
FCF Margin -126.12%
ROA -29.81%
ROE -55.12%
ROIC -55.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 1
Overweight 0
Hold 4
Underweight 0
Sell 0
What these ratings mean

Analyst Consensus: Overweight

Price Target

$12.50*
(5.66% upside)
Low
12.5
Current: $11.83
High
12.5
Target: 12.50
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Income Statement | Balance Sheet | Cash Flow
Year2019201820172016201520142013201220112010
Revenue43.220.500.901.040.650.340.07---
Revenue Growth8543.37%-44.33%-13.75%59.19%95.1%372.24%----
Gross Profit38.320.500.901.040.650.340.07---
Operating Income-79.25-86.29-68.56-38.89-37.63-28.99-23.98-6.47-2.73-2.26
Net Income-76.82-85.02-67.83-38.30-37.24-28.83-24.20-6.27-2.75-1.80
Shares Outstanding42.0928.3923.0617.8017.2912.9410.323.443.443.30
Earnings Per Share-1.83-2.99-2.94-2.15-2.15-2.23-2.35-1.82-0.802.81
Operating Cash Flow-67.69-72.18-49.62-30.09-25.59-25.71-16.12-4.13-1.94-1.86
Capital Expenditures-0.06-0.11-0.13-0.01-0.02--0.46---
Free Cash Flow-67.75-72.29-49.75-30.10-25.61-25.71-16.58-4.13-1.94-1.86
Cash & Equivalents16460.1151.7246.8846.0453.9844.202.035.830.00
Total Debt1.40------2.011.57-
Net Cash / Debt16360.1151.7246.8846.0453.9844.200.024.260.00
Assets18763.4967.0168.1298.2260.4985.285.036.45-
Liabilities23.3621.2919.9410.4010.105.085.667.543.25-
Book Value16442.2047.0757.7288.1155.4179.62-2.513.21-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Stemline Therapeutics, Inc.
Country United States
Employees 100
CEO Ivan Bergstein

Stock Information

Ticker Symbol STML
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: STML
IPO Date January 29, 2013

Description

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and Europe. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is headquartered in New York, New York.